AML is an aggressive blood cancer in which abnormal myeloid cells accumulate in the bone marrow and interfere with the production of normal blood cells. Mutations in the gene encoding FLT3, a receptor tyrosine kinase that transmits growth and survival signals, are among the most common genetic alterations found in AML. These mutations can cause FLT3 to remain abnormally active, encouraging leukemia cells to multiply rapidly and resist normal controls on growth. Several drugs, including gilteritinib, have been developed to block mutant FLT3, but patients frequently experience treatment resistance or relapse.

“FLT3 mutations are one of the most common genetic drivers of AML,” said corresponding author Dr. Daisuke Nakada, Henry and Emma Meyer Professor in Molecular and Human Genetics at Baylor College of Medicine. Earlier work had established that FLT3 inhibition can stop leukemia cells from dividing and activate apoptosis, a programmed self-destruction pathway. Nakada and his colleagues investigated whether the drugs might also kill AML cells through a mechanism that does not depend solely on apoptosis. Their experiments revealed that the answer is ferroptosis, a distinct process that is increasingly recognized as an important vulnerability in cancer.

Ferroptosis occurs when cells lose the ability to control lipid peroxidation. In this process, reactive oxygen molecules attack polyunsaturated fatty acids within cellular membranes, generating unstable lipid compounds that damage membrane structure and disrupt essential cellular functions. Unlike apoptosis, which involves an organized dismantling of the cell, ferroptosis is associated with catastrophic oxidative injury. The researchers observed evidence of this process in mouse models, laboratory leukemia cell lines and patient-derived AML samples transplanted into animals, demonstrating that the mechanism was not restricted to a single experimental system.

The team traced the vulnerability to GPX4, an enzyme that protects cell membranes from lipid peroxidation. GPX4 is a selenoprotein, meaning that it contains the trace element selenium as part of its active structure. By reducing harmful lipid peroxides, GPX4 acts as one of the cell’s most important defenses against ferroptosis. The researchers found that mutant FLT3 supports the production of GPX4 and other selenoproteins in AML cells. When FLT3 is blocked, this production is disrupted, leaving leukemia cells increasingly exposed to oxidative damage.

According to the study, the effect is not simply a matter of FLT3 inhibitors switching off a growth signal. The drugs also appear to interfere with the cellular machinery required to make selenoproteins. As GPX4 levels fall, AML cells become less capable of neutralizing lipid peroxides. The resulting accumulation of oxidized lipids pushes the cells beyond a critical threshold, triggering ferroptotic death. This connection between mutant FLT3 signaling, selenium-dependent protein production and ferroptosis provides a biochemical explanation for why FLT3-mutant leukemia may be particularly sensitive to the treatment.

Analysis of samples from AML patients offered additional clues about resistance. Leukemia samples that had become resistant to gilteritinib frequently showed increased activity in genes involved in selenoprotein production. The pattern suggests that resistant cells may survive by strengthening the very protective pathway that FLT3 inhibitors weaken. By increasing their capacity to synthesize GPX4 and related proteins, the cells could restore their ability to control lipid peroxidation even while FLT3 signaling remains suppressed. This observation raises the possibility that the selenoprotein pathway could serve as a biomarker of resistance or a target for combination therapies.

The researchers also identified a potential influence outside the cancer cell itself: dietary vitamin E. Vitamin E is an antioxidant that can limit lipid oxidation, and experiments showed that dietary supplementation markedly reduced the effectiveness of gilteritinib in animal models. The result does not establish that ordinary dietary intake compromises treatment, nor does it provide a basis for patients to change supplements without medical advice. It does, however, highlight the importance of understanding how antioxidants may affect therapies that depend on oxidative damage to eliminate cancer cells. High-dose vitamin E supplementation could theoretically suppress the ferroptotic mechanism activated by FLT3 inhibition.

The findings position ferroptosis as a possible therapeutic lever in FLT3-mutant AML and suggest several avenues for future research. Drugs that further weaken GPX4 activity, disrupt selenium metabolism or increase lipid peroxidation might enhance the effects of FLT3 inhibitors, particularly in resistant disease. At the same time, any such approach would require careful dosing because ferroptosis-related processes also occur in normal tissues. The study was conducted by scientists from Baylor College of Medicine, the University of Texas MD Anderson Cancer Center, Texas A&M University and Washington University School of Medicine, with support from federal, philanthropic and Texas-based research programs. Further clinical studies will be needed to determine whether manipulating ferroptosis can improve outcomes for people with AML.

Subject of Research: FLT3-mutant acute myeloid leukemia, ferroptosis and resistance to FLT3 inhibitors.

News Publication Date: Aug. 7, 2026.

Web References: Nature Cell Biology; https://doi.org/10.1038/s41556-026-02016-5

References: DOI: 10.1038/s41556-026-02016-5.

Keywords: acute myeloid leukemia, AML, FLT3, FLT3 inhibitors, gilteritinib, ferroptosis, GPX4, selenoproteins, lipid peroxidation, cancer therapy, drug resistance, vitamin E, leukemia research

Published in the esteemed journal Blood Cancer Discovery, this large-scale study represents the most comprehensive exploration to date focusing on patients receiving combination therapy involving venetoclax and hypomethylating agents (HMAs). By analyzing clinical and molecular data drawn from 678 AML patients, the research team has delineated how specific genetic aberrations in tandem with the developmental state of AML cells collaboratively dictate treatment responsiveness, unraveling complexities previously obscured in standard therapeutic paradigms.

Venetoclax, a potent inhibitor of the anti-apoptotic protein BCL-2, has emerged as a frontline therapeutic agent when combined with HMAs for newly diagnosed AML cases, especially in older adults with poor tolerance for intensive chemotherapy. Despite its promising clinical benefits and improved survival rates, a significant subset of patients exhibits primary resistance or experience disease relapse, hinting at underlying biological heterogeneity that impacts drug efficacy but remained poorly understood until now.

Dr. Daniel Pollyea, professor of medicine at the CU School of Medicine and lead investigator, emphasizes that the clinical heterogeneity seen in AML response patterns stems not only from genetic mutations but also from the cellular differentiation status of the leukemia. "Our study reveals that patient responses are tightly linked to both the mutational landscape and the maturation stage of leukemia cells present at diagnosis," Pollyea explains. This dual-factor model provides a more robust framework for risk stratification than previous mutation-centric approaches.

Critically, the team uncovered that patients with monocytic AML subtypes—characterized by more differentiated leukemic cells—demonstrated markedly poorer outcomes when lacking the favorable NPM1 mutation. These patients were also enriched for additional mutations such as KRAS, a gene frequently implicated in oncogenic signaling and chemoresistance. This constellation of molecular features underscores a distinct biological subset of AML with innate resistance pathways, challenging conventional treatment regimens.

Such findings carry profound clinical implications because they shed light on the ‘escape mechanisms’ leukemic cells deploy to circumvent venetoclax action. The maturation state of monocytic cells appears to enable alternative survival signaling routes, which effectively neutralize the drug’s pro-apoptotic intent. By integrating mutational profiling with cell differentiation markers, clinicians can now better predict which patients harbor such resistant clones and may require alternative or adjunctive therapies.

Historically, AML treatment strategies emphasized genetic abnormalities or cellular phenotypes independently, but this study’s integrative analysis approach reveals a synergistic effect, offering a more nuanced comprehension of therapeutic resistance. "It’s akin to unveiling a back door that cancer cells exploit to dodge treatment," notes Pollyea, highlighting the potential to develop novel agents or combination therapies designed to block these alternative pathways and improve remission durability.

This research not only refines prognostic models but also heralds a tangible shift toward personalized medicine in AML. Utilizing comprehensive molecular and phenotypic data at the point of diagnosis, healthcare providers can now better tailor therapeutic regimens to individual patients’ disease biology, enhancing the likelihood of response and reducing unnecessary exposure to ineffective treatments.

Further collaborative efforts are underway to enlarge the patient dataset and validate the predictive power of this combined model in prospective clinical trials. Pollyea and his colleagues envision forthcoming studies that will employ this knowledge to dynamically guide treatment decisions in real time, potentially transforming therapeutic outcomes in AML—a historically challenging and lethal cancer.

Institutions worldwide contributed to this collaborative effort, including the Knight Cancer Institute at Oregon Health and Science University, multiple French cancer centers such as Hôpital Lyon Sud and CHU Clermont-Ferrand, as well as the Lineberger Comprehensive Cancer Center at the University of North Carolina. Their collective expertise and pooled data resources were instrumental in identifying subtle yet critical biological distinctions within AML patient populations.

The University of Colorado Anschutz Medical Campus, home to the Cancer Center and a nexus of innovative research, continues to cement its role at the vanguard of hematological oncology advances. With robust funding exceeding $900 million annually, including public and philanthropic sources, the campus supports pioneering research endeavors aimed at confronting cancers like AML through cutting-edge science and multidisciplinary collaboration.

This study’s revelations mark an important step forward in decoding the biological variability that governs AML treatment success and failure, fostering hope for more effective, targeted interventions. As Dr. Pollyea articulates, approaching leukemia treatment with nuanced molecular precision not only improves individual patient journey but also pushes the entire field closer to enduring cures for this devastating disease.

Subject of Research: Acute Myeloid Leukemia (AML) treatment response variability based on genetic mutations and leukemia cell maturity.

Article Title: Understanding the Biological Drivers of Venetoclax Resistance in AML: Integrative Insights into Genetic and Cellular Determinants

News Publication Date: June 2024

Web References:

• University of Colorado Cancer Center: https://medschool.cuanschutz.edu/colorado-cancer-center
• Blood Cancer Discovery article: https://aacrjournals.org/bloodcancerdiscov/article/doi/10.1158/2643-3230.BCD-24-0256

Keywords: Acute Myeloid Leukemia, Venetoclax, Hypomethylating Agents, AML Treatment Resistance, NPM1 Mutation, KRAS Mutation, Cancer Cell Differentiation, Personalized Medicine, Hematologic Oncology, Genetic Biomarkers